Latest Breaking News On - Jonsson comprehensive cancer center tumor immunology program - Page 1 : comparemela.com

Woodcock’s extraordinary expertise will ensure excellent stewardship in her role as Acting FDA Commissioner PHILADELPHIA The American Association for Cancer Research (AACR), which consists of more than 47,000 laboratory, translational, and clinical researchers; other health care professionals; population scientists; and patient advocates, strongly supports President Biden’s decision to appoint Janet Woodcock, MD, as acting commissioner of the U.S. Food and Drug Administration (FDA). “We look forward to working with Dr. Woodcock and her dedicated colleagues at the FDA to ensure the approval of safe and effective treatments for patients with cancer,” said AACR President Antoni Ribas, MD, PhD, professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles, and director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program. “Throughout her more than three decades of stellar service at the FDA, Dr. Wood

United statesAntoni ribasJanet woodcockMargaret fotiUniversity of california los angelesAmerican association for cancer researchDavid geffen school of medicineJonsson comprehensive cancer center tumor immunology programDrug administrationAmerican associationCancer researchPresident bidenDavid geffen schoolCalifornia los angelesComprehensive cancer center tumor immunologyDrug evaluation